I could be wrong because I'm only guessing. But I think we get bought before we get FDA approval.
But I agree with Canis about each indication being approved separately for specific combo treatments instead of having the FDA approve some umbrella combo treatment that uses one combo to treat all appropriate cancer indications. But this very much works in our favor and I think PRH agrees. As we've seen over the last 1.5 years is PVCT starting numerous P1 trials or expanded cohorts for different indications. If TTC is correct about MUM being the one that is closest to getting FDA approval, then that might be what makes BP move. PRH's ability to show BP that PV-10 in combo will work in other indications other than MUM is where PRH are going to have leverage to negotiate a higher buyout price. Each indication that PV-10 can treat could add significant value to the buyout over the single indication the they initially chose to move on. If one BP wants PV-10 for one combo with their drug and another BP wants PV-10 for their combo, all the better for negotiations. PRH are setting this up and timing things perfectly.
But TTC could very well be correct if PVCT gains AA or BTD for an indication. That would be more of a sure thing/less risk for BP to buy at that point. It's important to have as much data about other indications before this happens to maximize price negotiation leverage.
Also, I'm VERY excited about the PH-10 clarification. I'd love to see BP buy PV-10 instead of the entire company all at once. Then we could take our massive cash position to maximize PH-10 value to it's fullest. But, getting money out of PH-10 sooner in order to expand PV-10 studies probably makes more sense.
But once again, I agree with Canis in his statement that this is the most interesting and most exciting Press Release that PRH has given the public and I'm VERY excited at where we're headed as a company.
I'll be adding more shares.